Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai), Martina Goetsch(Pfizer (United States)), Andrés Yarur(Cedars-Sinai Medical Center), Julián Panés(Hospital Clínic de Barcelona), Fabio Cataldi(Pfizer (United States)), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Silvio Danese(IRCCS Ospedale San Raffaele), Christopher J. Rabbat(Abivax (France)), Geert D’Haens(Amsterdam University Medical Centers), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Kevin Shan(Abivax (France)), Michael Chiorean(Swedish Medical Center), Douglas C. Wolf(Atlanta Gastroenterology Associates), Filip Baert(AZ Delta), Timothy E. Ritter(Unknown), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Sheldon Sloan(Pfizer (United States)), Séverine Vermeire(KU Leuven)
Cited by 350
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k